





PDX Data Sheet for COG-N-619x

Disease: Neuroblastoma

Phase of Therapy: Post-Chemotherapy (Progressive Disease), Post XRT **Treatment:** ANBL00B1 (Chemotherapy, Surgery), Radiation

Disease Stage: 4
Gender: Male

Age at diagnosis: 32.5 months

Race: NA

Age at sample collection: 40.7 months

Source of culture: Right Bone Marrow February 2016

Primary tumor site: Adrenal gland, NOS; Suprarenal gland; Adrenal, NOS

Date Established: May 2016

MYCN Patient: Non-Amplified

MYCN PDX: Relative copy number – 4 copies

TH mRNA: Expressed

p53 functionality: NA

Telomere Mechanism: TERT+, C-circle negative

ALK: Wild Type

PDX RNAseq: Available upon request PDX WES: Available upon request

Strain of Mice: NSG or Athymic NuNu (recommended)

Injection Type: Subcutaneous

Growth Properties: 10e6 cells minimum, ~5 months to 1500mm³

Please see Protocols section at https://www.cccells.org/protocols.php

Human vs. Mouse: This PDX model has been tested and confirmed over multiple passages to be

above 98% human cells.

STR Profile: May be obtained at https://strdb.cccells.org/

Notes: The Childhood Cancer Repository has a matching direct-to-culture cell line available from

this same patient – COG-N-619. The Childhood Cancer Repository has a matching hypoxic cell line grown at 5% O₂ and 2% O₂ available from this same patient – COG-N-619h and COG-N-619h2. There is a matching cell line with a PDX also available from this same patient but were established from right bone marrow – COG-N-618 and COG-N-618x.

h-IMPACT Profile I IDEXX: PCR evaluation of EBV, HAdV, Hantaan, HCMV, Hepatitis A, Hepatitis B, Hepatitis C, HHV 6, HHV8, HIV1, HIV2, HSV 1, HSV 2, HTLV 1, HTLV2, LCMV, Mycoplasma sp., Seoul,

Sin Nombre, VZV were all negative.







PDX Data Sheet for COG-N-619x

Cell Line Name: COG-N-619x

References:







PDX Data Sheet for COG-N-619x

PDX Name: COG-N-619x

H&E slides